NASDAQ:PBLA • US69833W4042
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PANBELA THERAPEUTICS INC (PBLA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-06-24 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-27 | Roth MKM | Maintains | Buy -> Buy |
| 2024-02-05 | Roth MKM | Maintains | Buy -> Buy |
| 2023-12-18 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-02 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-26 | HC Wainwright & Co. | Initiate | Buy |
| 2023-03-20 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-01-31 | Roth Capital | Reiterate | Buy |
| 2022-10-12 | Maxim Group | Downgrade | Buy -> Hold |
| 2021-06-28 | Roth Capital | Initiate | Buy |
| 2021-03-10 | Maxim Group | Initiate | Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 389.44% | N/A 194.12% | N/A 183.56% | N/A 34.84% | |||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A -11.06% | N/A -13.41% | N/A 2.36% | N/A 45.33% | N/A 175.95% | N/A | N/A | |
| EBIT YoY % growth | -5.44M | -5.17M 4.96% | -6.01M -16.25% | -3.89M 35.27% | -4.32M -11.05% | -5.75M -33.10% | -10.01M -74.09% | -34.09M -240.56% | N/A 30.03% | N/A -9.09% | N/A -30.30% | N/A -11.01% | N/A 101.19% | N/A 25,070.07% | N/A 274.04% | N/A 39.45% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | -25.83 99.85% | -5,796.00 -22,339.02% | N/A 96.41% | N/A 83.13% | N/A 11.53% | N/A 90.86% | N/A 109.35% | N/A 2,146.15% | N/A 180.65% | N/A 29.23% |
All data in USD
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -1.22 97.72% | -1.12 95.48% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -6.816M 13.18% | -6.884M -43.90% |
All data in USD
8 analysts have analysed PBLA and the average price target is 418.2 USD. This implies a price increase of 37575.68% is expected in the next year compared to the current price of 1.11.
PANBELA THERAPEUTICS INC (PBLA) will report earnings on 2024-05-02, after the market close.
The consensus EPS estimate for the next earnings of PANBELA THERAPEUTICS INC (PBLA) is -1.22 USD and the consensus revenue estimate is 0 USD.
The consensus rating for PANBELA THERAPEUTICS INC (PBLA) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.